Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia Clinical Trial

— XCL1  

Official title:

Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01380587
• Other study ID #: XCL1 in ALL
• Status: Completed
• Phase: N/A
• First received: June 22, 2011
• Last updated: August 26, 2013
• Start date: November 2010
• Est. completion date: September 2012

Study information

• Verified date: August 2013
• Source: Hospital Universitario Dr. Jose E. Gonzalez
• Contact: n/a
• Is FDA regulated: No
• Health authority: Mexico: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.

Description:

Each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue. It has been found with significant expression of receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: September 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

Patients with newly diagnosed acute lymphoblastic leukemia .

Exclusion Criteria:

• Patients with prior treatment with chemotherapeutic agents.

• Patients treated with immunosuppressants.

• Patients under 12 months old.

• Patients with a diagnosis or history of autoimmune diseases.

• Patients with a diagnosis or history of immunosuppressive diseases.

• Patients who do not agree to sign a Letter of Informed Consent.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Locations

Country	Name	City	State
Mexico	Hospital Universitario Dr. Jose E. Gonzalez UANL	Monterrey	Nuevo Leon

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Universitario Dr. Jose E. Gonzalez

Country where clinical trial is conducted

Mexico, 

References & Publications (6)

Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997 Feb 13;385(6617):640-4. — View Citation

Huang H, Li F, Cairns CM, Gordon JR, Xiang J. Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin. Biochem Biophys Res Commun. 2001 Feb 23;281(2):378-82. — View Citation

Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol. 1991;9:617-48. Review. — View Citation

Rollins BJ. Chemokines. Blood. 1997 Aug 1;90(3):909-28. Review. — View Citation

Stievano L, Tosello V, Marcato N, Rosato A, Sebelin A, Chieco-Bianchi L, Amadori A. CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes. J Immunol. 2003 Nov 1;171(9):4528-38. — View Citation

Taub DD, Oppenheim JJ. Chemokines, inflammation and the immune system. Ther Immunol. 1994 Aug;1(4):229-46. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with poor prognosis and high levels of XCL1	Number of patients with high levels of XCL1, expression of its receptor and other cytokines.	3 months	No
Primary	Number of patients with poor prognosis and high levels of cytokines	Measurements obtained will be evaluated to assess the prognosis of patients and made correlations with the concentration of IL-1ß, IL-2 and XCL1 as well as the relationship XCR1 XCL1 and in leukemic cells.	3 months	No